Nano X Imaging

NNOX

Market cap $206M

Collaboration with Adriamed drives commercial expansion and strengthens Nanox's regional leadership Engagement supports continued growth across multiple European markets, following recent collaborations in Greece, Romania, Czech Republic and France PETACH TIKVA, ISRAEL – January 14, 2026 – Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a new collaboration with Adriamed d.o.o.

Nano-X Imaging remains a 'sell' due to weak revenue growth, worsening losses, and limited traction in its core business. NNOX's advanced imaging technology and AI offerings have yet to translate into significant sales, with most revenue still from teleradiology services. Recent partnerships and acquisitions, including VasoHealthcare IT and European distribution deals, offer potential but lack a clear financial impact.

It signed a distribution deal with a French partner. This followed similar arrangements made in other European countries.

Althea France, part of  one of Europe's largest independent medical technology services provider s , to distribute CE-marked Nanox.ARC system across French healthcare sector

Nanox's HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated

PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses.

The visualization specialist posted its third quarter results. It beat on the bottom line and missed slightly on revenue, but investors were cheered by other developments.

Nano-X Imaging Ltd. ( NNOX ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Mike Cavanaugh - IR-ICR Westwicke Erez Meltzer - CEO & Acting Chairman of the Board Ran Daniel - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Scott Henry - Alliance Global Partners, Research Division Presentation Operator Good day, and thank you for standing by.

Vaso Corporation 137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact: Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW, N.Y, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, announced today that it had reached an agreement, subject to certain conditions, with Nano-X Imaging Ltd. (“Nanox”) (Nasdaq: NNOX), an innovative medical imaging technology company, to sell one of its subsidiaries, VasoHealthcare IT Corp. The parties intend to complete the sale within a couple of weeks.

PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties have agreed on the terms and conditions pursuant to which Nanox will acquire VasoHealthcare IT Inc . (“VHC IT”) from Vaso Corporation (“Vaso”) (OTCQX: VASO), subject to certain conditions.